Role of Salivary Immune Parameters in Patients With Primary Sjögren’s Syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Several factors, including clinical manifestations and laboratory data, have been used to evaluate the disease activity of Sjögren’s syndrome (SS). We investigated saliva indicators of disease activity in primary SS patients. Methods: We enrolled 138 Taiwanese patients with primary SS and 100 Taiwanese normal controls. Interleukin (IL)-6, IL-17A, tumor necrosis factor-alpha (TNF-α), and rheumatoid factor (RF)-IgA levels in saliva samples were measured using ELISA or fluorescent enzyme-linked immunoassay. Serum IgG, IgA, and IgM levels were measured by nephelometry. Erythrocyte sedimentation rate (ESR) was measured with an automatic ESR analyzer. The t-test and Pearson correlation test were used. Results: IL-6 level was higher in primary SS patients than in normal controls (14.23±14.77 vs 9.87±7.32, P=0.012), but there were no significant differences in IL-17A, TNF-α, and RF-IgA levels. In primary SS patients, IL-6 level correlated weakly with ESR and IgG levels (r=0.252, P=0.015, and r=0.248, P=0.017, respectively), and TNF-α level correlated weakly with IgG level (r=0.231, P=0.024). Conclusions: IL-6 may play a role in SS pathogenesis. Saliva IL-6 might be an indicator of disease activity in primary SS patients.
Abstract
Background: Several factors, including clinical manifestations and laboratory data, have been used to evaluate the disease activity of Sjögren’s syndrome (SS). We investigated saliva indicators of disease activity in primary SS patients. Methods: We enrolled 138 Taiwanese patients with primary SS and 100 Taiwanese normal controls. Interleukin (IL)-6, IL-17A, tumor necrosis factor-alpha (TNF-α), and rheumatoid factor (RF)-IgA levels in saliva samples were measured using ELISA or fluorescent enzyme-linked immunoassay. Serum IgG, IgA, and IgM levels were measured by nephelometry. Erythrocyte sedimentation rate (ESR) was measured with an automatic ESR analyzer. The t-test and Pearson correlation test were used. Results: IL-6 level was higher in primary SS patients than in normal controls (14.23±14.77 vs 9.87±7.32, P=0.012), but there were no significant differences in IL-17A, TNF-α, and RF-IgA levels. In primary SS patients, IL-6 level correlated weakly with ESR and IgG levels (r=0.252, P=0.015, and r=0.248, P=0.017, respectively), and TNF-α level correlated weakly with IgG level (r=0.231, P=0.024). Conclusions: IL-6 may play a role in SS pathogenesis. Saliva IL-6 might be an indicator of disease activity in primary SS patients.
참고문헌 (32)
- Ramos-Casals M, "Primary Sjogren’s syndrome : new clinical and therapeutic concepts", Ann Rheum Dis, 64, pp.347~354 (2005)
- Yu KH, "Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan", Arthritis Care Res, 65, pp.244~250 (2013)
- Cobb BL, "Genes and Sjogren’s syndrome", Rheum Dis Clin North Am, 34, pp.847~868 (2008)
- Lessard CJ, "Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome", Nat Genet, 45, pp.1284~1292 (2013)
- Li Y, "A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren’s syndrome at 7q11.23", Nat Genet, 45, pp.1361~1365 (2013)
- Hermann E, "Rheumatoid factors of immunoglobulin classes IgA, IgG and IgM : methods of determination and clinical value", Schweiz Med Wochenschr, 116, pp.1290~1297 (1986)
- Herrmann D, "IgE rheumatoid factor. Occurrence and diagnostic importance in comparison with IgM rheumatoid factor and circulating immune complexes", J Investig Allergol Clin Immunol, 1, pp.302~307 (1991)
- Banchuin N, "Re-evaluation of ELISA and latex agglutination test for rheumatoid factor detection in the diagnosis of rheumatoid arthritis", Asian Pac J Allergy Immunol, 10, pp.47~54 (1992)
- Martel C, "Active immunological profile is associated with systemic Sjogren’s syndrome", J Clin Immunol, 31, pp.840~847 (2011)
- Malladi AS, "Primary Sjogren’s syndrome as a systemic disease : a study of participants enrolled in an international Sjogren’s syndrome registry", Arthritis Care Res, 64, pp.911~918 (2012)
- Seror R, "EULAR Sjogren’s syndrome disease activity index : development of a consensus systemic disease activity index for primary Sjogren’s syndrome", Ann Rheum Dis, 69, pp.1103~1109 (2010)
- Ramos-Casals M, "Primary Sjogren syndrome : hematologic patterns of disease expression", Medicine, 81, pp.281~292 (2002)
- Quartuccio L, "Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjogren’s syndrome : results of a large multicentre study", Scand J Rheumatol, 44, pp.36~41 (2015)
- Ohyama K, "Saliva as a potential tool for diagnosis of dry mouth including Sjogren’s syndrome", Oral Dis, 21, pp.224~231 (2015)
- Nguyen CQ, "Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren’s syndrome : findings in humans and mice", Arthritis Rheum, 58, pp.734~743 (2008)
- Moriyama M, "Cytokine", chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjogren’s syndrome, 2012, pp.169, 17~26
- Vitali C, "Classification criteria for Sjogren’s syndrome : a revised version of the European criteria proposed by the American-European Consensus Group", Ann Rheum Dis, 61, pp.554~558 (2002)
- Roescher N, "Cytokines in Sjogren’s syndrome", Oral Dis, 15, pp.519~526 (2009)
- Benchabane S, "A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjogren’s syndrome", Int J Immunopathol Pharmacol, 29, pp.386~397 (2016)
- Fox RI, "Cytokine mRNA expression in salivary gland biopsies of Sjogren’s syndrome", J Immunol, 152, pp.5532~5539 (1994)
- Streckfus C, "Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren’s syndrome, secondary Sjögren’s syndrome, and patients with primary Sjögren’s syndrome receiving varying doses of interferon for symptomatic treatment of the condition : a preliminary study", Clin Oral Investig, 5, pp.133~135 (2001)
- Zhang LW, "Interleukin-17 impairs salivary tight junction integrity in Sjogren’s syndrome", J Dent Res, 95, pp.784~792 (2016)
- Nguyen CQ, "Pathogenic effect of interleukin-17A in induction of Sjogren’s syndrome-like disease using adenovirus-mediated gene transfer", Arthritis Res Ther, 12, pp.R220~ (2010)
- Lin X, "Th17 cells play a critical role in the development of experimental Sjogren’s syndrome", Ann Rheum Dis, 74, pp.1302~1310 (2015)
- Zhang LW, "Expression of interleukin-17 in primary Sjogren’s syndrome and the correlation with disease severity : a systematic review and meta-analysis", Scand J Immunol, 87, pp.e12649~ (2018)
- Azuma M, "Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB : a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren’s syndrome patients", Arthritis Rheum, 46, pp.1585~1594 (2002)
- Zhou J, "Pathogenic role of endogenous TNF-alpha in the development of Sjogren’s-like sialadenitis and secretory dysfunction in non-obese diabetic mice", Lab Invest, 97, pp.458~467 (2017)
- Kang EH, "Salivary cytokine profiles in primary Sjogren’s syndrome differ from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1", Th-2 ratios, 2011, pp.29, 970~976
- Aota K, "Targeting TNF-alpha suppresses the production of MMP-9 in human salivary gland cells", Arch Oral Biol, 58, pp.1761~1768 (2013)
- Mariette X, "Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS)", 50, pp.1270~1276 (2004)
- Fauchais AL, "Articular manifestations in primary Sjogren’s syndrome : clinical significance and prognosis of 188 patients", Rheumatology, 49, pp.1164~1172 (2010)
- Markusse HM, "Rheumatoid factor isotypes in serum and salivary fluid of patients with primary Sjogren’s syndrome", Clin Immunol Immunopathol, 66, pp.26~32 (1993)